SCHEMBL5723931

SCHEMBL5723931

CC(C)(C)C1CN(c2nc(CNC(=O)c3ccccc3)cs2)C1O[SiH](c1ccccc1)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.43
NPC1 O15118 2/20 0.43
MAPT P10636 2/20 0.38
ALDH1A1 P00352 3/20 0.38
HPGD P15428 2/20 0.36
MIF P14174 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ROCK2 O75116 2/20 0.36
ROCK1 Q13464 1/20 0.36
GRK2 P25098 1/20 0.35
LMNA P02545 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
RAB9A P51151 1/20 0.34
DNM1L O00429 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
MAPK14 Q16539 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5723661 0.90 NPC1 (0.33) KDM4ENPC1ALDH1A1HPGDSMN1; SMN2
SCHEMBL5723789 0.88 HPGD (0.52) KDM4ENPC1MAPTALDH1A1HPGD
SCHEMBL5723937 0.85 USP30 (0.33)
SCHEMBL5724296 0.83 KDM4E (0.44) KDM4EMAPTALDH1A1SMN1; SMN2LMNA
SCHEMBL5724737 0.81 LDHA (0.41) KDM4EALDH1A1L3MBTL1
SCHEMBL5724321 0.80 TDP1 (0.42) KDM4ENPC1MAPTALDH1A1HPGD
SCHEMBL5723990 0.80 HCRTR1 (0.32)
SCHEMBL5724343 0.79 HCRTR1 (0.34) NPC1SMN1; SMN2RAB9AKMT2A
SCHEMBL5724075 0.79 SCD (0.40)
SCHEMBL5724192 0.79 MAPT (0.36) KDM4EMAPTALDH1A1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1340757-B1 1-METHYLCARBAPENEM DERIVATIVES SANKYO CO (JP) 2006-10-11 EP disclosed
US-7001897-B2 1-methylcarbapenem derivatives SANKYO COMPANY, LIMITED (JP) 2006-02-21 US disclosed
US-20040014962-A1 1-Methylcarbapenem derivatives SANKYO COMPANY, LIMITED (JP) 2004-01-22 US disclosed
EP-1340757-A1 1-METHYLCARBAPENEM DERIVATIVES Sankyo Company, Limited (JP) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014962-A1 1-Methylcarbapenem derivatives CD14, CPT1A, ACMSD KDM4E 328/4885NPC1 383/4885MAPT 2574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.